Corrigendum to “The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions” [Thromb. Res. 212 (2022) 72–80] (Thrombosis Research (2022) 212 (72–80), (S0049384822000640), (10.1016/j.thromres.2022.02.020))

M. F.A. Karel; B. M.E. Tullemans; G. D'Italia; T. P. Lemmens; T. A.M. Claushuis; M. J.E. Kuijpers; J. M.E.M. Cosemans

doi:10.1016/j.thromres.2022.03.012

Corrigendum to “The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions” [Thromb. Res. 212 (2022) 72–80] (Thrombosis Research (2022) 212 (72–80), (S0049384822000640), (10.1016/j.thromres.2022.02.020))

M. F.A. Karel
, B. M.E. Tullemans
, G. D'Italia
, T. P. Lemmens
, T. A.M. Claushuis
, M. J.E. Kuijpers
, J. M.E.M. Cosemans^*

^*Corresponding author for this work

Maastricht University

Research output: Contribution to journal › Comment/Letter to the editor › Academic

11 Downloads (Pure)

Abstract

The authors regret that the bars of Fig. 3 published in the article lacked color and that * were missing. Below is the correct Fig. 3. [Figure presented] The authors would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	113
Number of pages	1
Journal	Thrombosis research
Volume	213
DOIs	https://doi.org/10.1016/j.thromres.2022.03.012
Publication status	Published - May 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.thromres.2022.03.012

Corrigendum-to-the-effect-of-brutons-tyrosine-kinase-inhibitor-ibrutinib-on-atherothrombus-formation-under-stenotic-fl.pdfFinal published version, 314 KBLicence: CC BY

Fingerprint

Dive into the research topics of 'Corrigendum to “The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions” [Thromb. Res. 212 (2022) 72–80] (Thrombosis Research (2022) 212 (72–80), (S0049384822000640), (10.1016/j.thromres.2022.02.020))'. Together they form a unique fingerprint.

Cite this

Karel, M. F. A., Tullemans, B. M. E., D'Italia, G., Lemmens, T. P., Claushuis, T. A. M., Kuijpers, M. J. E., & Cosemans, J. M. E. M. (2022). Corrigendum to “The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions” [Thromb. Res. 212 (2022) 72–80] (Thrombosis Research (2022) 212 (72–80), (S0049384822000640), (10.1016/j.thromres.2022.02.020)). Thrombosis research, 213, 113. https://doi.org/10.1016/j.thromres.2022.03.012

Karel, M. F.A. ; Tullemans, B. M.E. ; D'Italia, G. et al. / Corrigendum to “The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions” [Thromb. Res. 212 (2022) 72–80] (Thrombosis Research (2022) 212 (72–80), (S0049384822000640), (10.1016/j.thromres.2022.02.020)). In: Thrombosis research. 2022 ; Vol. 213. pp. 113.

@article{1dd8c6498ecb4844af514b1c63cc4a67,

title = "Corrigendum to {\textquotedblleft}The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions{\textquotedblright} [Thromb. Res. 212 (2022) 72{\textendash}80] (Thrombosis Research (2022) 212 (72{\textendash}80), (S0049384822000640), (10.1016/j.thromres.2022.02.020))",

abstract = "The authors regret that the bars of Fig. 3 published in the article lacked color and that * were missing. Below is the correct Fig. 3. [Figure presented] The authors would like to apologise for any inconvenience caused.",

author = "Karel, \{M. F.A.\} and Tullemans, \{B. M.E.\} and G. D'Italia and Lemmens, \{T. P.\} and Claushuis, \{T. A.M.\} and Kuijpers, \{M. J.E.\} and Cosemans, \{J. M.E.M.\}",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = may,

doi = "10.1016/j.thromres.2022.03.012",

language = "English",

volume = "213",

pages = "113",

journal = "Thrombosis research",

issn = "0049-3848",

publisher = "Elsevier Limited",

}

Karel, MFA, Tullemans, BME, D'Italia, G, Lemmens, TP, Claushuis, TAM, Kuijpers, MJE & Cosemans, JMEM 2022, 'Corrigendum to “The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions” [Thromb. Res. 212 (2022) 72–80] (Thrombosis Research (2022) 212 (72–80), (S0049384822000640), (10.1016/j.thromres.2022.02.020))', Thrombosis research, vol. 213, pp. 113. https://doi.org/10.1016/j.thromres.2022.03.012

Corrigendum to “The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions” [Thromb. Res. 212 (2022) 72–80] (Thrombosis Research (2022) 212 (72–80), (S0049384822000640), (10.1016/j.thromres.2022.02.020)). / Karel, M. F.A.; Tullemans, B. M.E.; D'Italia, G. et al.
In: Thrombosis research, Vol. 213, 05.2022, p. 113.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Corrigendum to “The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions” [Thromb. Res. 212 (2022) 72–80] (Thrombosis Research (2022) 212 (72–80), (S0049384822000640), (10.1016/j.thromres.2022.02.020))

AU - Karel, M. F.A.

AU - Tullemans, B. M.E.

AU - D'Italia, G.

AU - Lemmens, T. P.

AU - Claushuis, T. A.M.

AU - Kuijpers, M. J.E.

AU - Cosemans, J. M.E.M.

PY - 2022/5

Y1 - 2022/5

N2 - The authors regret that the bars of Fig. 3 published in the article lacked color and that * were missing. Below is the correct Fig. 3. [Figure presented] The authors would like to apologise for any inconvenience caused.

AB - The authors regret that the bars of Fig. 3 published in the article lacked color and that * were missing. Below is the correct Fig. 3. [Figure presented] The authors would like to apologise for any inconvenience caused.

UR - https://www.scopus.com/pages/publications/85126853458

U2 - 10.1016/j.thromres.2022.03.012

DO - 10.1016/j.thromres.2022.03.012

M3 - Comment/Letter to the editor

C2 - 35334440

AN - SCOPUS:85126853458

SN - 0049-3848

VL - 213

SP - 113

JO - Thrombosis research

JF - Thrombosis research

ER -

Karel MFA, Tullemans BME, D'Italia G, Lemmens TP, Claushuis TAM, Kuijpers MJE et al. Corrigendum to “The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions” [Thromb. Res. 212 (2022) 72–80] (Thrombosis Research (2022) 212 (72–80), (S0049384822000640), (10.1016/j.thromres.2022.02.020)). Thrombosis research. 2022 May;213:113. doi: 10.1016/j.thromres.2022.03.012

Corrigendum to “The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions” [Thromb. Res. 212 (2022) 72–80] (Thrombosis Research (2022) 212 (72–80), (S0049384822000640), (10.1016/j.thromres.2022.02.020))

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this